RET-positive NSCLC: Translating insights into targeted approaches
Update: 2025-05-15
Description
touchFOCUS for touchONCOLOGY
In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.
The expert:
- Dr Christine Bestvina - University of Chicago, Chicago, IL, USA
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc.
This activity is jointly provided by USF Health and touchIME.
For further information visit our website: touchoncology.com
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
